Ferrochelatase is a therapeutic target for ocular neovascularization

Abstract

Ocular neovascularization underlies major blinding eye diseases such as “wet” age-related macular degeneration (AMD). Despite the successes of treatments targeting the vascular endothelial growth factor (VEGF) pathway, resistant and refractory patient populations necessitate discovery of new therapeutic targets. Using a forward chemical genetic approach, we identified the heme synthesis enzyme ferrochelatase (FECH) as necessary for angiogenesis in vitro and in vivo. FECH is overexpressed in wet AMD eyes and murine choroidal neovascularization; siRNA knockdown of Fech or partial loss of enzymatic function in the Fechm1Pas mouse model reduces choroidal neovascularization. FECH depletion modulates endothelial nitric oxide synthase function and VEGF receptor 2 levels. FECH is inhibited by the oral antifungal drug griseofulvin, and this compound ameliorates choroidal neovascularization in mice when delivered intravitreally or orally. Thus, FECH inhibition could be used therapeutically to block ocular neovascularization.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Basavarajappa, H. D., Sulaiman, R. S., Qi, X., Shetty, T., Babu, S. S. P., Sishtla, K. L., ... & Gupta, K. (2017). Ferrochelatase is a therapeutic target for ocular neovascularization. EMBO Molecular Medicine. http://dx.doi.org/10.15252/emmm.201606561
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
EMBO Molecular Medicine
Source
Publisher
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Final published version
Full Text Available at
This item is under embargo {{howLong}}